Lauren classification and individualized chemotherapy in gastric cancer

Junli Ma, Hong Shen, Linda Kapesa, Shan Zeng, Junli Ma, Hong Shen, Linda Kapesa, Shan Zeng

Abstract

Gastric cancer is one of the most common malignancies worldwide. During the last 50 years, the histological classification of gastric carcinoma has been largely based on Lauren's criteria, in which gastric cancer is classified into two major histological subtypes, namely intestinal type and diffuse type adenocarcinoma. This classification was introduced in 1965, and remains currently widely accepted and employed, since it constitutes a simple and robust classification approach. The two histological subtypes of gastric cancer proposed by the Lauren classification exhibit a number of distinct clinical and molecular characteristics, including histogenesis, cell differentiation, epidemiology, etiology, carcinogenesis, biological behaviors and prognosis. Gastric cancer exhibits varied sensitivity to chemotherapy drugs and significant heterogeneity; therefore, the disease may be a target for individualized therapy. The Lauren classification may provide the basis for individualized treatment for advanced gastric cancer, which is increasingly gaining attention in the scientific field. However, few studies have investigated individualized treatment that is guided by pathological classification. The aim of the current review is to analyze the two major histological subtypes of gastric cancer, as proposed by the Lauren classification, and to discuss the implications of this for personalized chemotherapy.

Keywords: Lauren classification; diffuse type; gastric cancer; individualized chemotherapy; intestinal type.

References

    1. Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: Descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23:700–713. doi: 10.1158/1055-9965.EPI-13-1057.
    1. Guggenheim DE, Shah MA. Gastric cancer epidemiology and risk factors. J Surg Oncol. 2013;107:230–236. doi: 10.1002/jso.23262.
    1. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12:354–362. doi: 10.3748/wjg.v12.i3.354.
    1. Patru CL, Surlin V, Georgescu I, Patru E. Current issues in gastric cancer epidemiology. Rev Med Chir Soc Med Nat Iasi. 2013;117:199–204.
    1. Lauren P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.
    1. Qiu MZ, Cai MY, Zhang DS, Wang ZQ, Wang DS, Li YH, Xu RH. Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China. J Transl Med. 2013;11:58. doi: 10.1186/1479-5876-11-58.
    1. Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Miwa S, Tsuneyama K, Takano Y. Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: An immunostaining study on the tissue microarray. J Clin Pathol. 2007;60:273–277. doi: 10.1136/jcp.2006.038778.
    1. Chen YC, Fang WL, Wang RF, Liu CA, Yang MH, Lo SS, Wu CW, Li AF, Shyr YM, Huang KH. Clinicopathological variation of lauren classification in gastric cancer. Pathol Oncol Res. 2016;22:197–202. doi: 10.1007/s12253-015-9996-6.
    1. Hommel C, Knoedler M, Bojarski C, Schumann M, Epple HJ, Zeitz M, Daum S. Diffuse gastric cancer with peritoneal carcinomatosis can mimic Crohn's disease. Case Rep Gastroenterol. 2012;6:695–703. doi: 10.1159/000345385.
    1. Stiekema J, Cats A, Kuijpers A, van Coevorden F, Boot H, Jansen EP, Verheij M, Ponz Balague O, Hauptmann M, van Sandick JW. Surgical treatment results of intestinal and diffuse type gastric cancer. Implications for a differentiated therapeutic approach? Eur J Surg Oncol. 2013;39:686–693. doi: 10.1016/j.ejso.2013.02.026.
    1. Kaneko S, Yoshimura T. Time trend analysis of gastric cancer incidence in Japan by histological types, 1975–1989. Br J Cancer. 2001;84:400–405. doi: 10.1054/bjoc.2000.1602.
    1. Yamamoto E, Suzuki H, Takamaru H, Yamamoto H, Toyota M, Shinomura Y. Role of DNA methylation in the development of diffuse-type gastric cancer. Digestion. 2011;83:241–249. doi: 10.1159/000320453.
    1. Fu DG. Epigenetic alterations in gastric cancer. Mol Med Rep. 2015;12:3223–3230. (Review)
    1. Martínez-Madrigal F, Ortiz-Hidalgo C, Torres-Vega C, Alvarez L, Manzo-Montaño A, García-López L, Esquivel-Ayanegui F. Atypical regenerative changes, dysplasia, and carcinoma in situ in chronic gastritis associated with Helicobacter pylori. Rev Gastroenterol Mex. 2000;65:11–17. (In Spanish)
    1. Kodama M, Murakami K, Okimoto T, Abe T, Nakagawa Y, Mizukami K, Uchida M, Inoue K, Fujioka T. Helicobacter pylori eradication improves gastric atrophy and intestinal metaplasia in long-term observation. Digestion. 2012;85:126–130. doi: 10.1159/000334684.
    1. Asaka M. Elimination of gastric cancer from Japan. Nihon Rinsho. 2012;70:1667–1672. (In Japanese)
    1. Take S, Mizuno M, Ishiki K, Yoshida T, Ohara N, Yokota K, Oguma K, Okada H, Yamamoto K. The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori. J Gastroenterol. 2011;46:318–324. doi: 10.1007/s00535-010-0347-9.
    1. Vannella L, Lahner E, Annibale B. Risk for gastric neoplasias in patients with chronic atrophic gastritis: A critical reappraisal. World J Gastroenterol. 2012;18:1279–1285. doi: 10.3748/wjg.v18.i12.1279.
    1. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. The long-term impact of Helicobacter pylori eradication on gastric histology: A systematic review and meta-analysis. Helicobacter. 2007;12(Suppl 2):S32–S38. doi: 10.1111/j.1523-5378.2007.00563.x.
    1. Maehata Y, Nakamura S, Fujisawa K, Esaki M, Moriyama T, Asano K, Fuyuno Y, Yamaguchi K, Egashira I, Kim H, et al. Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest Endosc. 2012;75:39–46. doi: 10.1016/j.gie.2011.08.030.
    1. Pereyra L, Gómez EJ, Mella JM, Casas G, Bugari G, Cimmino D, Pedreira S, Boerr LA. Diffuse gastric cancer associated with Ménétrier's disease. Acta Gastroenterol Latinoam. 2011;41:142–145. (In Spanish)
    1. Palestro G, Pellicano R, Fronda GR, Valente G, De Giuli M, Soldati T, Pugliese A, Taraglio S, Garino M, Campra D, et al. Prevalence of Helicobacter pylori infection and intestinal metaplasia in subjects who had undergone surgery for gastric adenocarcinoma in Northwest Italy. World J Gastroenterol. 2005;11:7131–7135. doi: 10.3748/wjg.v11.i45.7131.
    1. Nardone G, Rocco A, Malfertheiner P. Review article: Helicobacter pylori and molecular events in precancerous gastric lesions. Aliment Pharmacol Ther. 2004;20:261–270. doi: 10.1111/j.1365-2036.2004.02075.x.
    1. Yoshida T, Kato J, Maekita T, Yamashita S, Enomoto S, Ando T, Niwa T, Deguchi H, Ueda K, Inoue I, et al. Altered mucosal DNA methylation in parallel with highly active Helicobacter pylori-related gastritis. Gastric Cancer. 2013;16:488–497. doi: 10.1007/s10120-012-0230-x.
    1. Corso G, Marrelli D, Roviello F. Familial gastric cancer: Update for practice management. Fam Cancer. 2011;10:391–396. doi: 10.1007/s10689-010-9410-1.
    1. Oliveira C, Pinheiro H, Figueiredo J, Seruca R, Carneiro F. Familial gastric cancer: Genetic susceptibility, pathology, and implications for management. Lancet Oncol. 2015;16:e60–e70. doi: 10.1016/S1470-2045(14)71016-2.
    1. Vogelaar IP, van der Post RS, Bisseling TM, van Krieken JH, Ligtenberg MJ, Hoogerbrugge N. Familial gastric cancer: Detection of a hereditary cause helps to understand its etiology. Hered Cancer Clin Pract. 2012;10:18. doi: 10.1186/1897-4287-10-18.
    1. Carneiro F. Hereditary gastric cancer. Pathologe. 2012;33(Suppl 2):S231–S234. doi: 10.1007/s00292-012-1677-6.
    1. Machado JC, Oliveira C, Carvalho R, Soares P, Berx G, Caldas C, Seruca R, Carneiro F, Sobrinho-Simöes M. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene. 2001;20:1525–1528. doi: 10.1038/sj.onc.1204234.
    1. Kim IJ, Kang HC, Shin Y, Park HW, Jang SG, Han SY, Lim SK, Lee MR, Chang HJ, Ku JL, et al. A TP53-truncating germline mutation (E287X) in a family with characteristics of both hereditary diffuse gastric cancer and Li-Fraumeni syndrome. J Hum Genet. 2004;49:591–595. doi: 10.1007/s10038-004-0193-9.
    1. Kim S, Chung JW, Jeong TD, Park YS, Lee JH, Ahn JY, Kim DH, Choi KD, Lee W, Song HJ, et al. Searching for E-cadherin gene mutations in early onset diffuse gastric cancer and hereditary diffuse gastric cancer in Korean patients. Fam Cancer. 2013;12:503–507. doi: 10.1007/s10689-012-9595-6.
    1. Bacani JT, Soares M, Zwingerman R, di Nicola N, Senz J, Riddell R, Huntsman DG, Gallinger S. CDH1/E-cadherin germline mutations in early-onset gastric cancer. J Med Genet. 2006;43:867–872. doi: 10.1136/jmg.2006.043133.
    1. Corso G, Pedrazzani C, Pinheiro H, Fernandes E, Marrelli D, Rinnovati A, Pascale V, Seruca R, Oliveira C, Roviello F. E-cadherin genetic screening and clinico-pathologic characteristics of early onset gastric cancer. Eur J Cancer. 2011;47:631–639. doi: 10.1016/j.ejca.2010.10.011.
    1. Humar B, Graziano F, Cascinu S, Catalano V, Ruzzo AM, Magnani M, Toro T, Burchill T, Futschik ME, Merriman T, Guilford P. Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. Oncogene. 2002;21:8192–8195. doi: 10.1038/sj.onc.1205921.
    1. Liu YC, Shen CY, Wu HS, Hsieh TY, Chan DC, Chen CJ, Yu JC, Yu CP, Harn HJ, Chen PJ, et al. Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas. World J Gastroenterol. 2006;12:2168–2173. doi: 10.3748/wjg.v12.i14.2161.
    1. Ramos-de la Medina A, More H, Medina-Franco H, Humar B, Gamboa A, Ortiz LJ, Donohue JH, Guilford P. Single nucleotide polymorphisms (SNPs) at CDH1 promoter region in familial gastric cancer. Rev Esp Enferm Dig. 2006;98:36–41. doi: 10.4321/S1130-01082006000100005.
    1. Hoogerbrugge N, Ligtenberg MJ, Nagengast FM, Bonenkamp JJ, van Krieken JH. Preventive resection of hereditary diffuse gastric cancer. Ned Tijdschr Geneeskd. 2006;150:2417–2420. (In Dutch)
    1. Kluijt I, Sijmons RH, Hoogerbrugge N, Vasen HF, Cats A. Familial gastric cancer: Diagnosis, treatment and periodic surveillance. Ned Tijdschr Geneeskd. 2011;155:A2731. (In Dutch)
    1. Schildberg CW, Abba M, Merkel S, Agaimy A, Dimmler A, Schlabrakowski A, Croner R, Leupold JH, Hohenberger W, Allgayer H. Gastric cancer patients less than 50 years of age exhibit significant downregulation of E-cadherin and CDX2 compared to older reference populations. Adv Med Sci. 2014;59:142–146. doi: 10.1016/j.advms.2014.03.002.
    1. Kim H, An JY, Noh SH, Shin SK, Lee YC, Kim H. High microsatellite instability predicts good prognosis in intestinal-type gastric cancers. J Gastroenterol Hepatol. 2011;26:585–592. doi: 10.1111/j.1440-1746.2010.06487.x.
    1. Qiu M, Zhou Y, Zhang X, Wang Z, Wang F, Shao J, Lu J, Jin Y, Wei X, Zhang D, et al. Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients. BMC Cancer. 2014;14:823. doi: 10.1186/1471-2407-14-823.
    1. Wu ZY, Zhan WH, Li JH, He YL, Wang JP, Lan P, Peng JS, Cai SR. Expression of E-cadherin in gastric carcinoma and its correlation with lymph node micrometastasis. World J Gastroenterol. 2005;11:3139–3143. doi: 10.3748/wjg.v11.i20.3139.
    1. Lazăr D, Tăban S, Ardeleanu C, Dema A, Sporea I, Cornianu M, Lazăr E, Vernic C. The immunohistochemical expression of E-cadherin in gastric cancer; correlations with clinicopathological factors and patients' survival. Rom J Morphol Embryol. 2008;49:459–467.
    1. Stănculescu D, Mărgăritescu C, Stepan A, Mitruţ AO. E-cadherin in gastric carcinomas related to histological prognostic parameters. Rom J Morphol Embryol. 2011;52(Suppl 3):S1107–S1112.
    1. Karayiannakis AJ, Syrigos KN, Chatzigianni E, Papanikolaou S, Karatzas G. E-cadherin expression as a differentiation marker in gastric cancer. Hepatogastroenterology. 1998;45:2437–2442.
    1. Asano N, Imatani A, Watanabe T, Fushiya J, Kondo Y, Jin X, Ara N, Uno K, Iijima K, Koike T, et al. Cdx2 expression and intestinal metaplasia induced by H. pylori infection of gastric cells is regulated by NOD1-mediated innate immune responses. Cancer Res. 2016 Jan 12; doi: 10.1158/0008-5472.CAN-15-2272. (Epub ahead of print)
    1. Almeida R, Almeida J, Shoshkes M, Mendes N, Mesquita P, Silva E, Van Seuningen I, Reis CA, Santos-Silva F, David L. OCT-1 is over-expressed in intestinal metaplasia and intestinal gastric carcinomas and binds to, but does not transactivate, CDX2 in gastric cells. J Pathol. 2005;207:396–401. doi: 10.1002/path.1861.
    1. Mesquita P, Jonckheere N, Almeida R, Ducourouble MP, Serpa J, Silva E, Pigny P, Silva FS, Reis C, Silberg D, et al. Human MUC2 mucin gene is transcriptionally regulated by Cdx homeodomain proteins in gastrointestinal carcinoma cell lines. J Biol Chem. 2003;278:51549–51556. doi: 10.1074/jbc.M309019200.
    1. Kim HS, Lee JS, Freund JN, Min KW, Lee JS, Kim W, Juhng SW, Park CS. CDX-2 homeobox gene expression in human gastric carcinoma and precursor lesions. J Gastroenterol Hepatol. 2006;21:438–442. doi: 10.1111/j.1440-1746.2005.03933.x.
    1. Seno H, Oshima M, Taniguchi MA, Usami K, Ishikawa TO, Chiba T, Taketo MM. CDX2 expression in the stomach with intestinal metaplasia and intestinal-type cancer: Prognostic implications. Int J Oncol. 2002;21:769–774.
    1. Mizoshita T, Tsukamoto T, Nakanishi H, Inada K, Ogasawara N, Joh T, Itoh M, Yamamura Y, Tatematsu M. Expression of Cdx2 and the phenotype of advanced gastric cancers: Relationship with prognosis. J Cancer Res Clin Oncol. 2003;129:727–734. doi: 10.1007/s00432-003-0499-6.
    1. Fan Z, Li J, Dong B, Huang X. Expression of Cdx2 and hepatocyte antigen in gastric carcinoma: Correlation with histologic type and implications for prognosis. Clin Cancer Res. 2005;11:6162–6170. doi: 10.1158/1078-0432.CCR-05-0278.
    1. Fang WL, Chang SC, Lan YT, Huang KH, Chen JH, Lo SS, Hsieh MC, Li AF, Wu CW, Chiou SH. Microsatellite instability is associated with a better prognosis for gastric cancer patients after curative surgery. World J Surg. 2012;36:2131–2138. doi: 10.1007/s00268-012-1652-7.
    1. Kim JY, Shin NR, Kim A, Lee HJ, Park WY, Kim JY, Lee CH, Huh GY, Park DY. Microsatellite instability status in gastric cancer: A reappraisal of its clinical significance and relationship with mucin phenotypes. Korean J Pathol. 2013;47:28–35. doi: 10.4132/KoreanJPathol.2013.47.1.28.
    1. Yuan DD, Zhu ZX, Zhang X, Liu J. Targeted therapy for gastric cancer: Current status and future directions. Oncol Rep. 2016;35:1245–1254. (Review)
    1. Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Yoo CH, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci. 2006;51:1371–1379. doi: 10.1007/s10620-005-9057-1.
    1. Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, Altmannsberger HM, Robinson E, Tafe LJ, Tang LH, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: A European and USA International collaborative analysis. Ann Oncol. 2012;23:2656–2662. doi: 10.1093/annonc/mds104.
    1. Sornmayura P, Rerkamnuaychoke B, Jinawath A, Euanorasetr C. Human epidermal growth-factor receptor 2 overexpression in gastric carcinoma in Thai patients. J Med Assoc Thai. 2012;95:88–95.
    1. Ishida M, Kagawa S, Shimoyama K, Takehara K, Noma K, Tanabe S, Shirakawa Y, Tazawa H, Kobayashi H, Fujiwara T. Trastuzumab-based photoimmunotherapy integrated with viral HER2 transduction inhibits peritoneally disseminated HER2-negative cancer. Mol Cancer Ther. 2016 Feb 1; doi: 10.1158/1535-7163.MCT-15-0644. (Epub ahead of print)
    1. Gagliato DM, Jardim DL, Marchesi MS, Hortobagyi GN. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. Oncotarget. 2016
    1. Liu W, Zhong S, Chen J, Yu Y. HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients. J Clin Gastroenterol. 2012;46:e31–e37. doi: 10.1097/MCG.0b013e31823457ea.
    1. Wu HM, Liu YH, Lin F, Xu FP, Luo DL, Zhang F, Zhuang HG, Luo XL, Wu WL, Lin XT. Association of HER2 protein expression with clinicopathologic features and prognosis in Chinese patients with gastric carcinoma. Zhonghua Bing Li Xue Za Zhi. 2011;40:296–299. (In Chinese)
    1. Förster S, Gretschel S, Jöns T, Yashiro M, Kemmner W. THBS4, a novel stromal molecule of diffuse-type gastric adenocarcinomas, identified by transcriptome-wide expression profiling. Mod Pathol. 2011;24:1390–1403. doi: 10.1038/modpathol.2011.99.
    1. Kim MA, Lee HS, Yang HK, Kim WH. Clinicopathologic and protein expression differences between cardia carcinoma and noncardia carcinoma of the stomach. Cancer. 2005;103:1439–1446. doi: 10.1002/cncr.20966.
    1. Zhao W, Zhu H, Zhang S, Yong H, Wang W, Zhou Y, Wang B, Wen J, Qiu Z, Ding G, et al. Trop2 is overexpressed in gastric cancer and predicts poor prognosis. Oncotarget. 2015 Dec 22; (Epub ahead of print)
    1. He HY, Wang XF, Shen ZB, Chen WD, Sun YH. Association of transcriptional repressor Snail with Lauren classification of gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 2012;15:852–854. (In Chinese)
    1. Jackson C, Mochlinski K, Cunningham D. Therapeutic options in gastric cancer: neoadjuvant chemotherapy vs postoperative chemoradiotherapy. Oncology (Williston Park) 2007;21:1084–1087. 1090, 1096–1098, 1101.
    1. Park SR, Kong SY, Nam BH, Choi IJ, Kim CG, Lee JY, Cho SJ, Kim YW, Ryu KW, Lee JH, et al. CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients. Br J Cancer. 2011;104:1126–1134. doi: 10.1038/bjc.2011.24.
    1. Wang Z, Chen JQ, Liu JL, Qin XG, Huang Y. Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: A systematic review. BMC Gastroenterol. 2012;12:137. doi: 10.1186/1471-230X-12-137.
    1. Takahari D, Boku N, Mizusawa J, Takashima A, Yamada Y, Yoshino T, Yamazaki K, Koizumi W, Fukase K, Yamaguchi K, et al. Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912. Oncologist. 2014;19:358–366. doi: 10.1634/theoncologist.2013-0306.
    1. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: The FLAGS trial. J Clin Oncol. 2010;28:1547–1553. doi: 10.1200/JCO.2009.25.4706.
    1. Narahara H, Iishi H, Imamura H, Tsuburaya A, Chin K, Imamoto H, Esaki T, Furukawa H, Hamada C, Sakata Y. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002) Gastric Cancer. 2011;14:72–80. doi: 10.1007/s10120-011-0009-5.
    1. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, et al. Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: A randomised phase 3 study. Lancet Oncol. 2009;10:1063–1069. doi: 10.1016/S1470-2045(09)70259-1.
    1. Yamaguchi K, Tada M, Horikoshi N, Otani T, Takiuchi H, Saitoh S, Kanamaru R, Kasai Y, Koizumi W, Sakata Y, Taguchi T. Paclitaxel Gastric Cancer Study Group in Japan: Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer. 2002;5:90–95. doi: 10.1007/s101200200015.
    1. Kato K, Chin K, Yoshikawa T, Yamaguchi K, Tsuji Y, Esaki T, Sakai K, Kimura M, Hamaguchi T, Shimada Y, et al. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest New Drugs. 2012;30:1621–1627. doi: 10.1007/s10637-011-9709-2.
    1. Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, Hara T, Chung HC, Satoh T, Cho JY, et al. JACCRO and KCSG Study Group: Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: A randomized study (START) J Cancer Res Clin Oncol. 2014;140:319–328. doi: 10.1007/s00432-013-1563-5.
    1. Kobayashi M, Sakamoto J, Namikawa T, Okamoto K, Okabayashi T, Ichikawa K, Araki K. Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients. World J Gastroenterol. 2006;12:1412–1415. doi: 10.3748/wjg.v12.i9.1412.
    1. Kitayama J, Ishigami H, Yamaguchi H, Yamashita H, Emoto S, Kaisaki S. S-1 plus intravenous and intraperitoneal Paclitaxel for gastric cancer with peritoneal metastasis. Gastrointest Cancer Res. 2012;5(Suppl 1):S10–S13.
    1. Toriumi F, Kubota T, Saikawa Y, Yoshida M, Otani Y, Watanabe M, Kumai K, Kitajima M. Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma. Anticancer Res. 2004;24:2455–2463.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe